gip and glp 1 receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology The clinically most relevant mechanisms
Description
Semaglutide is a GLP-1 receptor agonist that helps regulate blood sugar and appetite
In clinical trials, once-weekly semaglutide at diabetes doses (0.51 mg) produces mean weight loss of 46 kg (913 lbs), while the 2.4 mg dose (Wegovy) achieves average weight reductions of 1215% of body weight
PLoS One 10(9)
Effectiveness of Semaglutide vs
Ann Pharmacother (2017) 51:4019
After reaching your weight loss goal on a therapeutic dose, you reduce to the lowest dose that maintains your results
